arrow
T

Tetsuji Takayama

tokushima university graduate school of medicine
H指数:48
被引数:9,185

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

durvalumab联合tremelimumab治疗肝细胞癌患者淋巴细胞计数早期变化可预测临床结局

2026-10-070
OAAI
Comparing the Effect of Changes in Alcohol Intake on Liver Fibrosis Risk Scores Among Patients With Two Distinct Types of Steatotic Liver Disease

比较酒精摄入变化对两种不同类型脂肪性肝病患者的肝纤维化风险评分的影响

2026-09-080
PRE
Orthotopic Esophageal Cancer Xenograft Model in Immunosuppressed Microminipigs for Near-Infrared Fluorescence Endoscopy

免疫抑制条件下微小型猪的原位食管癌异种移植模型用于近红外荧光内镜检查

2026-04-030
OAAI
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B

阿特珠单抗联合贝伐珠单抗在Child-Pugh B级肝细胞癌患者中的有效性与安全性

2025-11-280
OAAI
Clinicopathological features and prognosis of metastatic tumors in the small bowel: a large multicenter analysis of the JSCCR database in Japan

小肠转移性肿瘤的临床病理特征与预后:基于日本JSCCR数据库的多中心大样本分析

2025-11-180
OAAI
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者接受阿特珠单抗联合贝伐珠单抗治疗后序贯免疫检查点抑制剂再治疗的结局

2025-11-010
OAAI
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study

代谢相关脂肪性肝病与度伐利尤单抗和特瑞普利单抗在晚期肝细胞癌患者临床结局中的关联:一项多中心研究

2025-08-210
PRE
Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment

在FOLFIRINOX治疗后,脂质体伊立替康联合氟尿嘧啶和亚叶酸钙用于不可切除胰腺癌的有效使用条件

2025-04-230
OA
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
2025-02-280
PRE
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma

durvalumab联合tremelimumab治疗不可切除的肝细胞癌的抗肿瘤作用和免疫介导的不良事件

2024-12-150
OA
The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease
2024-09-231
PRE
Association of variabilities in body mass index and waist circumference with newly achieved remission of metabolic dysfunction-associated fatty liver disease
2024-05-012
PRE
Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study
2024-02-290
PRE
Clinicopathological features and prognosis of primary small bowel adenocarcinoma: a large multicenter analysis of the JSCCR database in Japan
2024-02-271
OAAI
Gastric fundic gland polyposis and cancer development after eradication of Helicobacter pylori in patient with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)

胃腺癌和胃近端息肉病 (GAPPS) 患者根除幽门螺杆菌后胃底腺息肉病和癌症发展

2024-02-260
PRE